International Wex Technologies Inc.: Tectin'TM' Phase II Trial Begins in China.

VANCOUVER, British Columbia -- International Wex Technologies Inc. (TSX:WXI) (the "Company") is pleased to announce that the Tectin(TM) Phase II clinical trial in China has commenced to demonstrate the analgesic efficacy of Tectin(TM) in patients with chronic cancer pain. This is an efficacy trial in which an initial phase of escalating dose to the effective dose (Part I) is followed by a controlled phase (Part II). The total participants for Part I and Part II are approximately 300 patients, and will involve up to 8 SFDA (State Food and Drug Administration) authorized centers across China.

Part I study protocol has been approved by the local Ethic's Committee. This is an open-label, ascending dose efficacy and safety study of Tectin(TM) in late-stage cancer patients with severe pain. This entire Phase II study is expected to be completed within one year.

International Wex Technologies Inc., a publicly listed neuro-bioscience company (WXI), is focused on the development and commercialization of innovative drug products, primarily for pain management. The Company's lead compound, Tetrodotoxin, a sodium channel blocker, is the platform for the Company's development of a portfolio of proprietary products in the field of analgesia, drug addiction withdrawal treatment, and local anaesthesia.

Per: Donna Shum, Corporate Secretary

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.